Works by Nishio, Makoto

Results: 125
    1
    2
    3
    4

    Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

    Published in:
    NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00170-7
    By:
    • Yoshizawa, Takahiro;
    • Uchibori, Ken;
    • Araki, Mitsugu;
    • Matsumoto, Shigeyuki;
    • Ma, Biao;
    • Kanada, Ryo;
    • Seto, Yosuke;
    • Oh-hara, Tomoko;
    • Koike, Sumie;
    • Ariyasu, Ryo;
    • Kitazono, Satoru;
    • Ninomiya, Hironori;
    • Takeuchi, Kengo;
    • Yanagitani, Noriko;
    • Takagi, Satoshi;
    • Kishi, Kazuma;
    • Fujita, Naoya;
    • Okuno, Yasushi;
    • Nishio, Makoto;
    • Katayama, Ryohei
    Publication type:
    Article
    5
    6
    7

    Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.

    Published in:
    Japanese Journal of Clinical Oncology, 2021, v. 51, n. 1, p. 106, doi. 10.1093/jjco/hyaa157
    By:
    • Saka, Hideo;
    • Nishio, Makoto;
    • Hida, Toyoaki;
    • Nakagawa, Kazuhiko;
    • Sakai, Hiroshi;
    • Nogami, Naoyuki;
    • Atagi, Shinji;
    • Takahashi, Toshiaki;
    • Horinouchi, Hidehito;
    • Takenoyama, Mitsuhiro;
    • Katakami, Nobuyuki;
    • Tanaka, Hiroshi;
    • Takeda, Koji;
    • Satouchi, Miyako;
    • Isobe, Hiroshi;
    • Maemondo, Makoto;
    • Goto, Koichi;
    • Hirashima, Tomonori;
    • Minato, Koichi;
    • Yada, Nobumichi
    Publication type:
    Article
    8

    Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

    Published in:
    Japanese Journal of Clinical Oncology, 2018, v. 48, n. 4, p. 367, doi. 10.1093/jjco/hyy016
    By:
    • Katsuyuki Kiura;
    • Fumio Imamura;
    • Hiroshi Kagamu;
    • Shingo Matsumoto;
    • Toyoaki Hida;
    • Kazuhiko Nakagawa;
    • Miyako Satouchi;
    • Isamu Okamoto;
    • Mitsuhiro Takenoyama;
    • Yasuhito Fujisaka;
    • Takayasu Kurata;
    • Masayuki Ito;
    • Kota Tokushige;
    • Hatano, Ben;
    • Makoto Nishio
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.

    Published in:
    2018
    By:
    • Sasaki, Tomonari;
    • Seto, Takashi;
    • Yamanaka, Takeharu;
    • Kunitake, Naonobu;
    • Shimizu, Junichi;
    • Kodaira, Takeshi;
    • Nishio, Makoto;
    • Kozuka, Takuyo;
    • Takahashi, Toshiaki;
    • Harada, Hideyuki;
    • Yoshimura, Naruo;
    • Tsutsumi, Shinichi;
    • Kitajima, Hiromoto;
    • Kataoka, Masaaki;
    • Ichinose, Yukito;
    • Nakagawa, Kazuhiko;
    • Nishimura, Yasumasa;
    • Yamamoto, Nobuyuki;
    • Nakanishi, Yoichi
    Publication type:
    journal article
    20
    21
    22

    Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

    Published in:
    2013
    By:
    • Okamoto, Isamu;
    • Aoe, Keisuke;
    • Kato, Terufumi;
    • Hosomi, Yukio;
    • Yokoyama, Akira;
    • Imamura, Fumio;
    • Kiura, Katsuyuki;
    • Hirashima, Tomonori;
    • Nishio, Makoto;
    • Nogami, Naoyuki;
    • Okamoto, Hiroaki;
    • Saka, Hideo;
    • Yamamoto, Nobuyuki;
    • Yoshizuka, Naoto;
    • Sekiguchi, Risa;
    • Kiyosawa, Kazuhiro;
    • Nakagawa, Kazuhiko;
    • Tamura, Tomohide
    Publication type:
    Journal Article
    23

    Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

    Published in:
    Investigational New Drugs, 2013, v. 31, n. 5, p. 1275, doi. 10.1007/s10637-013-9941-z
    By:
    • Okamoto, Isamu;
    • Aoe, Keisuke;
    • Kato, Terufumi;
    • Hosomi, Yukio;
    • Yokoyama, Akira;
    • Imamura, Fumio;
    • Kiura, Katsuyuki;
    • Hirashima, Tomonori;
    • Nishio, Makoto;
    • Nogami, Naoyuki;
    • Okamoto, Hiroaki;
    • Saka, Hideo;
    • Yamamoto, Nobuyuki;
    • Yoshizuka, Naoto;
    • Sekiguchi, Risa;
    • Kiyosawa, Kazuhiro;
    • Nakagawa, Kazuhiko;
    • Tamura, Tomohide
    Publication type:
    Article
    24

    Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

    Published in:
    2013
    By:
    • Okamoto, Isamu;
    • Aoe, Keisuke;
    • Kato, Terufumi;
    • Hosomi, Yukio;
    • Yokoyama, Akira;
    • Imamura, Fumio;
    • Kiura, Katsuyuki;
    • Hirashima, Tomonori;
    • Nishio, Makoto;
    • Nogami, Naoyuki;
    • Okamoto, Hiroaki;
    • Saka, Hideo;
    • Yamamoto, Nobuyuki;
    • Yoshizuka, Naoto;
    • Sekiguchi, Risa;
    • Kiyosawa, Kazuhiro;
    • Nakagawa, Kazuhiko;
    • Tamura, Tomohide
    Publication type:
    Correction Notice
    25
    26
    27
    28

    First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.

    Published in:
    International Journal of Clinical Oncology, 2023, v. 28, n. 10, p. 1354, doi. 10.1007/s10147-023-02390-2
    By:
    • Nishio, Makoto;
    • Ohe, Yuichiro;
    • Ikeda, Satoshi;
    • Yokoyama, Toshihide;
    • Hayashi, Hidetoshi;
    • Fukuhara, Tatsuro;
    • Sato, Yuki;
    • Tanaka, Hiroshi;
    • Hotta, Katsuyuki;
    • Sugawara, Shunichi;
    • Daga, Haruko;
    • Okamoto, Isamu;
    • Kasahara, Kazuo;
    • Naito, Tateaki;
    • Li, Li;
    • Gupta, Ravi G.;
    • Bushong, Judith;
    • Mizutani, Hideaki
    Publication type:
    Article
    29
    30
    31

    Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1828, doi. 10.1007/s10147-022-02232-7
    By:
    • Sugawara, Shunichi;
    • Kondo, Masashi;
    • Yokoyama, Toshihide;
    • Kumagai, Toru;
    • Nishio, Makoto;
    • Goto, Koichi;
    • Nakagawa, Kazuhiko;
    • Seto, Takashi;
    • Yamamoto, Nobuyuki;
    • Kudou, Kentarou;
    • Asato, Takayuki;
    • Zhang, Pingkuan;
    • Ohe, Yuichiro
    Publication type:
    Article
    32
    33
    34
    35

    Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

    Published in:
    International Journal of Clinical Oncology, 2019, v. 24, n. 5, p. 485, doi. 10.1007/s10147-019-01396-z
    By:
    • Sugawara, Shunichi;
    • Nakagawa, Kazuhiko;
    • Yamamoto, Nobuyuki;
    • Nokihara, Hiroshi;
    • Ohe, Yuichiro;
    • Nishio, Makoto;
    • Takahashi, Toshiaki;
    • Goto, Koichi;
    • Maemondo, Makoto;
    • Ichinose, Yukito;
    • Seto, Takashi;
    • Sakai, Hiroshi;
    • Gemma, Akihiko;
    • Imamura, Fumio;
    • Shingyoji, Masato;
    • Saka, Hideo;
    • Inoue, Akira;
    • Takeda, Koji;
    • Okamoto, Isamu;
    • Kiura, Katsuyuki
    Publication type:
    Article
    36

    Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

    Published in:
    International Journal of Clinical Oncology, 2017, v. 22, n. 1, p. 70, doi. 10.1007/s10147-016-1039-0
    By:
    • Yamamoto, Noboru;
    • Goto, Koichi;
    • Nishio, Makoto;
    • Chikamori, Kenichi;
    • Hida, Toyoaki;
    • Maemondo, Makoto;
    • Katakami, Nobuyuki;
    • Kozuki, Toshiyuki;
    • Yoshioka, Hiroshige;
    • Seto, Takashi;
    • Tajima, Kosei;
    • Tamura, Tomohide
    Publication type:
    Article
    37
    38
    39
    40
    41
    42

    Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01).

    Published in:
    Thoracic Cancer, 2023, v. 14, n. 2, p. 168, doi. 10.1111/1759-7714.14729
    By:
    • Uematsu, Shinya;
    • Kitazono, Satoru;
    • Tanaka, Hisashi;
    • Saito, Ryota;
    • Kawashima, Yosuke;
    • Ohyanagi, Fumiyoshi;
    • Tozuka, Takehiro;
    • Ryosuke, Tsugitomi;
    • Sakatani, Toshio;
    • Horiike, Atsushi;
    • Yoshizawa, Takahiro;
    • Saiki, Masafumi;
    • Tambo, Yuichi;
    • Koyama, Junji;
    • Kanazu, Masaki;
    • Kudo, Keita;
    • Tsuchiya‐Kawano, Yuko;
    • Yanagitani, Noriko;
    • Nishio, Makoto
    Publication type:
    Article
    43
    44

    Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02).

    Published in:
    Thoracic Cancer, 2022, v. 13, n. 10, p. 1471, doi. 10.1111/1759-7714.14415
    By:
    • Tanaka, Hisashi;
    • Sakamoto, Hiroaki;
    • Akita, Takahiro;
    • Ohyanagi, Fumiyoshi;
    • Kawashima, Yosuke;
    • Tambo, Yuichi;
    • Tanimoto, Azusa;
    • Horiike, Atsushi;
    • Miyauchi, Eisaku;
    • Tsuchiya‐Kawano, Yuko;
    • Yanagitani, Noriko;
    • Nishio, Makoto
    Publication type:
    Article
    45
    46
    47
    48
    49
    50